Nobelpharma

Quick facts

Phase 3 pipeline

• IKH-01 · Diabetes
  IKH-01 is a small molecule that targets the SGLT2 receptor.
• Norethisterone,Ethinylestradiol · Women's Health
  Norethisterone is a progestogen that acts as an agonist of the progesterone receptor, while ethinylestradiol is an estrogen that acts as an agonist of the estrogen receptor.
• NPC-01 · Diabetes
  NPC-01 is a small molecule that targets the SGLT2 receptor.
• NPC-02 · Diabetes
  NPC-02 is a small molecule that targets the SGLT2 receptor.
• NPC-07 for oral administration · Diabetes
  NPC-07 is a small molecule that targets the SGLT2 receptor.
• NPC-09 · Diabetes
  NPC-09 is a small molecule that targets the SGLT2 receptor.
• NPC-12Y gel · Dermatology/Wound Care
  NPC-12Y is a topical gel formulation designed to promote wound healing and tissue regeneration through growth factor delivery.
• NPC-15 · Diabetes
  NPC-15 is a small molecule that targets the SGLT2 receptor.
• NPC-16 Continuous Dosing Regimen Group · Immunology
  NPC-16 is a small molecule that targets the sphingosine-1-phosphate receptor 1 (S1PR1) to modulate immune cell trafficking.
• NPC-16 Standard Dosing Regimen Group · Immunology
  NPC-16 is a small molecule that targets the sphingosine-1-phosphate receptor 1 (S1PR1) to modulate immune responses.

Phase 2 pipeline

• NPC-15 Granules Higher Dose
• NPC-15 Granules Lower Dose
• NPC-21 High dose
• NPC-21 Low dose

Phase 1 pipeline

• NPC-08
• NPC-22

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Nobelpharma portfolio CI brief
• Nobelpharma pipeline updates RSS